標題: Titlebook: HCV: The Journey from Discovery to a Cure; Volume II Michael J. Sofia Book 2019 Springer Nature Switzerland AG 2019 NS5B Inhibitors.NS4B In [打印本頁] 作者: Enkephalin 時間: 2025-3-21 16:16
書目名稱HCV: The Journey from Discovery to a Cure影響因子(影響力)
書目名稱HCV: The Journey from Discovery to a Cure影響因子(影響力)學科排名
書目名稱HCV: The Journey from Discovery to a Cure網(wǎng)絡(luò)公開度
書目名稱HCV: The Journey from Discovery to a Cure網(wǎng)絡(luò)公開度學科排名
書目名稱HCV: The Journey from Discovery to a Cure被引頻次
書目名稱HCV: The Journey from Discovery to a Cure被引頻次學科排名
書目名稱HCV: The Journey from Discovery to a Cure年度引用
書目名稱HCV: The Journey from Discovery to a Cure年度引用學科排名
書目名稱HCV: The Journey from Discovery to a Cure讀者反饋
書目名稱HCV: The Journey from Discovery to a Cure讀者反饋學科排名
作者: 明智的人 時間: 2025-3-21 23:49 作者: 拋媚眼 時間: 2025-3-22 00:47 作者: Astigmatism 時間: 2025-3-22 04:37
978-3-030-28402-2Springer Nature Switzerland AG 2019作者: conspicuous 時間: 2025-3-22 09:55
HCV: The Journey from Discovery to a Cure978-3-030-28400-8Series ISSN 1862-2461 Series E-ISSN 1862-247X 作者: forager 時間: 2025-3-22 15:41
Book 2019he major causes of liver cancer and liver transplants. The elucidation of the HCV genome, and the development of a whole cell system to study the virus spurred the search for novel direct acting antiviral drugs to cure this disease. This global effort culminated in the development of direct acting a作者: 令人不快 時間: 2025-3-22 17:46 作者: 煉油廠 時間: 2025-3-22 22:40 作者: conference 時間: 2025-3-23 03:31 作者: Gratulate 時間: 2025-3-23 07:25 作者: 調(diào)整 時間: 2025-3-23 11:15
Evolution of HCV NS4B Inhibitorsemical classes taken into account. To date, the only clinical trial conducted with molecules targeting NS4B was focused on clemizole hydrochloride. However, even if NS4B ligands are not currently used in therapy, they can serve in the near future as new weapons to combat resistance to the current therapy.作者: 葡萄糖 時間: 2025-3-23 15:17
Beijing International IT R&D Hub IT R&D Hub,efforts and refinement of the core structure ultimately led to the identification of elbasvir, a ring-constrained tetracyclic indole-based analogue of MK-4882 which showed increased potency against clinical resistance variants and an improved resistance profile.作者: Constituent 時間: 2025-3-23 19:48
to better understanding the strengths and limitations of DAA treatment among unique populations of patients with chronic hepatitis C who were underrepresented in the original registration trials of these agents.作者: Decrepit 時間: 2025-3-24 02:16
Discovery of Elbasvirefforts and refinement of the core structure ultimately led to the identification of elbasvir, a ring-constrained tetracyclic indole-based analogue of MK-4882 which showed increased potency against clinical resistance variants and an improved resistance profile.作者: defeatist 時間: 2025-3-24 05:08 作者: 獸群 時間: 2025-3-24 09:20 作者: 吸引力 時間: 2025-3-24 11:21 作者: 易碎 時間: 2025-3-24 16:58
The Chimpanzees of Bossou and Nimbambined daclatasvir (.) with the protease inhibitor asunaprevir (.) established that a chronic HCV infection could be cured with small molecule therapy in the absence of immune stimulation, setting the stage for approval of this regimen for the treatment of GT-1b-infected subjects by the Japanese hea作者: 量被毀壞 時間: 2025-3-24 20:21 作者: FLAG 時間: 2025-3-25 00:22 作者: 洞穴 時間: 2025-3-25 03:55
https://doi.org/10.1057/9780230363410rology, has been solidified based on the combination of our understanding of the molecular biology of the virus and the rarity, dating back to the interferon era, of virologic relapse after attainment of sustained virologic response. Although, at least until recently, the number of therapeutic agent作者: Orchiectomy 時間: 2025-3-25 09:41 作者: 使腐爛 時間: 2025-3-25 14:10
Ss). The Phase 3 studies enrolled and treated over 1,000 genotype 1–6 HCV-infected patients with 12?weeks of SOF/VEL. In patients with compensated cirrhosis, the overall SVR rate was 98%, and with SOF/VEL?+?RBV in patients with decompensated cirrhosis, the SVR rate was 94%. With minimal drug-drug in作者: oxidant 時間: 2025-3-25 15:54 作者: Rodent 時間: 2025-3-25 21:39 作者: intercede 時間: 2025-3-26 03:47 作者: 興奮過度 時間: 2025-3-26 04:20
r to SVR underwent a biopsy after SVR. However, the post-SVR liver biopsies of only 4 patients showed F1–F2, while 11 patients still showed F3–F4, indicating that TE improvements are overstated when compared to histologic staging and that patients with cirrhosis before DAA therapy need to be monitor作者: Culpable 時間: 2025-3-26 10:53 作者: 排名真古怪 時間: 2025-3-26 13:57
1862-2461 l provide a one of a kind reference work that highlights the many efforts, from the discovery of the HCV virus, to the invention of breakthrough medicines and their use in the real world to cure patients. It is978-3-030-28402-2978-3-030-28400-8Series ISSN 1862-2461 Series E-ISSN 1862-247X 作者: 預感 時間: 2025-3-26 17:53
The Discovery and Development of Daclatasvir: An Inhibitor of the Hepatitis C Virus NS5A Replicationmbined daclatasvir (.) with the protease inhibitor asunaprevir (.) established that a chronic HCV infection could be cured with small molecule therapy in the absence of immune stimulation, setting the stage for approval of this regimen for the treatment of GT-1b-infected subjects by the Japanese hea作者: 不在灌木叢中 時間: 2025-3-27 00:28 作者: 巧思 時間: 2025-3-27 01:26
HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombroved IFN-sparing DAA therapies (Viekira Pak? and Technivie?) with approval to treat genotypes 1 and 4, respectively. PIB, a next-generation NS5A inhibitor included in AbbVie’s next-generation therapy Mavyret? (or Maviret?), prevents replication of HCV genotypes 1–6 and exhibits an improved resistan作者: Virtues 時間: 2025-3-27 08:46
The Evolution of Clinical Trials for Hepatitis Crology, has been solidified based on the combination of our understanding of the molecular biology of the virus and the rarity, dating back to the interferon era, of virologic relapse after attainment of sustained virologic response. Although, at least until recently, the number of therapeutic agent作者: Malaise 時間: 2025-3-27 12:05 作者: ARY 時間: 2025-3-27 16:06
The Clinical Development of Sofosbuvir/Velpatasvir (SOF/VEL, Epclusa?)Ss). The Phase 3 studies enrolled and treated over 1,000 genotype 1–6 HCV-infected patients with 12?weeks of SOF/VEL. In patients with compensated cirrhosis, the overall SVR rate was 98%, and with SOF/VEL?+?RBV in patients with decompensated cirrhosis, the SVR rate was 94%. With minimal drug-drug in作者: phlegm 時間: 2025-3-27 19:46 作者: 繁榮地區(qū) 時間: 2025-3-27 23:39 作者: thrombosis 時間: 2025-3-28 03:50
Development of ZEPATIER?to the approval of the elbasvir/grazoprevir combination therapy for the treatment of people with HCV genotype 1 or genotype 4 infection in the United States, Europe, Canada, and many other countries worldwide.作者: prostate-gland 時間: 2025-3-28 08:24
The Benefit of Direct-Acting Antiviral HCV Cure Therapiesr to SVR underwent a biopsy after SVR. However, the post-SVR liver biopsies of only 4 patients showed F1–F2, while 11 patients still showed F3–F4, indicating that TE improvements are overstated when compared to histologic staging and that patients with cirrhosis before DAA therapy need to be monitor作者: 配偶 時間: 2025-3-28 13:37
NS5A as a Target for HCV Drug Discoveryfort by academic and pharmaceutical researchers, HCV infection is a curable disease. In fact, HCV is the first chronic infectious disease to be cured with combinations of direct antiviral agents. Among these antiviral agents, NS5A inhibitors are the most potent. The unprecedented low pM potency, pan作者: forecast 時間: 2025-3-28 14:45 作者: neolith 時間: 2025-3-28 18:57 作者: Aggregate 時間: 2025-3-29 00:08
The Discovery of Velpatasvir (GS-5816): The Potent Pan-Genotypic Once-Daily Oral HCV NS5A Inhibitor ipasvir and the nonstructural 5B protein (NS5B) nucleotide inhibitor sofosbuvir (SOF), provided a major advancement in the treatment of individuals with chronic genotype 1 (GT1) HCV infection. Herein is described the discovery of velpatasvir (VEL, GS-5816), a pan-genotypic NS5A inhibitor with low pi作者: CT-angiography 時間: 2025-3-29 06:43
Discovery of Elbasvirand the NS3/4A protease inhibitor grazoprevir) for the treatment of adult patients with chronic hepatitis C virus genotype 1 or genotype 4 infection. The discovery of elbasvir (EBR) was the result of a concerted research effort within Merck’s newly formed External Basic Research (also, EBR) group an作者: 確保 時間: 2025-3-29 11:08 作者: Alveoli 時間: 2025-3-29 11:32
Evolution of HCV NS4B Inhibitorso 2016 led to the identification of different chemical classes targeting NS4B as effective anti-HCV agents, and some of them act by impairing AH2-mediated membranous web formation or RNA-binding property. This book chapter aims to discuss research published on NS4B inhibitors focusing on hit identif作者: interpose 時間: 2025-3-29 17:50
The Evolution of Clinical Trials for Hepatitis C-sought discovery of the causative agent, ranks as a landmark achievement of modern medicine. In the broadest sense, the international effort to address this global public health problem can be divided into an era of nonspecifically targeted therapy centering on interferon, a relatively brief “hybri作者: 截斷 時間: 2025-3-29 21:32 作者: B-cell 時間: 2025-3-30 00:08
The Clinical Development of Sofosbuvir/Velpatasvir (SOF/VEL, Epclusa?) inhibitor, provides a highly efficacious, safe, and simple treatment regimen for patients with genotype 1–6 HCV infection. The clinical development program for SOF/VEL focused on generating safety and efficacy data across a broad range of patient populations to support a single treatment duration f作者: 人造 時間: 2025-3-30 07:01 作者: Femine 時間: 2025-3-30 11:54 作者: extinct 時間: 2025-3-30 12:47
Development of ZEPATIER? (HCV) infection. This novel direct-acting antiviral (DAA) regimen combines elbasvir, a selective inhibitor of the HCV nonstructural protein 5A, and grazoprevir, a reversible competitive inhibitor of the HCV nonstructural protein 3/4A protease. After extensive preclinical testing and evaluation of s作者: CHYME 時間: 2025-3-30 17:23
Real-World Evidence and Hepatitis Cions and safety among those with all stages of liver disease, including cirrhosis, have been repeatedly demonstrated in studies encompassing all classes of DAAs. Real-world evidence has confirmed that DAA therapies used in usual clinical practice achieved similar rates of sustained virological respo作者: 詳細目錄 時間: 2025-3-30 23:03 作者: 單挑 時間: 2025-3-31 03:49 作者: harangue 時間: 2025-3-31 08:44 作者: synovial-joint 時間: 2025-3-31 09:20
